Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

Shenton Research

Shenton Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Index Rebalance

<ul>
<li>NIFTY 50 rebalance will be effective on 30 Sep 2026 before market open, with one ADD and one DELETE.</li>
<li>BSE fell 13.9% and Wipro fell 12.9% over the bridge window to 28 Sep 2026, with one session left before implementation.</li>
<li>Historically, ADDs and DELETEs with a negative bridge mostly gained in the first implementation week.</li>
</ul>


NIFTY 50 rebalance will be effective on 30 Sep 2026 before market open, with one ADD and one DELETE.
BSE fell 13.9% and Wipro fell 12.9% over the bridge window to 28 Sep 2026, with one session left before implementation.
Historically, ADDs and DELETEs with a negative bridge mostly gained in the first implementation week.


NIFTY 50 Sep 2026 Rebalance: Pre-Implementation Update